Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent medication--an alternative?

W Gaebel1

  • 1Department of Psychiatry, Heinrich Heine University, Düsseldorf, Germany.

Acta Psychiatrica Scandinavica. Supplementum
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risks of digitalization in mental health care.

Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater·2025
Same author

EPA guidance on treatment of negative symptoms in schizophrenia.

European psychiatry : the journal of the Association of European Psychiatrists·2021
Same author

EPA guidance on assessment of negative symptoms in schizophrenia.

European psychiatry : the journal of the Association of European Psychiatrists·2021
Same author

EPA guidance on the quality of mental health services: A systematic meta-review and update of recommendations focusing on care coordination.

European psychiatry : the journal of the Association of European Psychiatrists·2020
Same author

[Quality psychiatry and destigmatization : Can quality psychiatry and psychotherapy contribute to destigmatization of mental illnesses?]

Der Nervenarzt·2020
Same author

Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study.

Epidemiology and psychiatric sciences·2020
Same journal

Use of psychotropic drugs during pregnancy and breast-feeding.

Acta psychiatrica Scandinavica. Supplementum·2015
Same journal

Getting depression clinical practice guidelines right: time for change?

Acta psychiatrica Scandinavica. Supplementum·2013
Same journal

Manipulating melatonin in managing mood.

Acta psychiatrica Scandinavica. Supplementum·2013
Same journal

Chronobiology of mood disorders.

Acta psychiatrica Scandinavica. Supplementum·2013
Same journal

It is time we managed depression: the emerging role of chronobiology. Preface.

Acta psychiatrica Scandinavica. Supplementum·2013
Same journal

Lifestyle management of unipolar depression.

Acta psychiatrica Scandinavica. Supplementum·2013
See all related articles

Neuroleptic maintenance medication effectively prevents schizophrenia relapse but has risks. Low-dose strategies and early intervention show promise, though intermittent treatment is not recommended for most patients.

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience
  • Clinical Psychology

Background:

  • Neuroleptic maintenance medication is a cornerstone for preventing schizophrenia relapse.
  • Individual patient responses vary, with some experiencing treatment failures or adverse effects like tardive dyskinesia.
  • Predicting the individual risk-benefit ratio of maintenance therapy necessitates exploring alternative strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of modified neuroleptic treatment strategies for schizophrenia relapse prevention.
  • To compare low-dose neuroleptic treatment and intermittent neuroleptic treatment against standard maintenance therapy.

Main Methods:

  • Review of controlled studies comparing standard-dose neuroleptic maintenance with low-dose strategies.

Related Experiment Videos

  • Analysis of recent 2-year controlled studies on early intervention and intermittent neuroleptic treatment versus maintenance therapy.
  • Assessment of relapse rates, side effects, and social adjustment in different treatment arms.

    • Main Results:

    • Low-dose neuroleptic treatment strategies demonstrate favorable outcomes in relapse prevention and side effect profiles compared to standard doses.
    • Intermittent neuroleptic treatment strategies, while reducing overall drug exposure and maintaining social adjustment, were not as effective as maintenance treatment in preventing relapses.
    • Controlled 2-year studies did not support intermittent treatment as a viable alternative to maintenance therapy for the majority of schizophrenia patients.

    Conclusions:

    • Low-dose neuroleptic maintenance therapy represents a promising modification for schizophrenia treatment.
    • Intermittent neuroleptic treatment is not recommended as a substitute for maintenance therapy due to lower efficacy in relapse prevention.
    • Further research into personalized risk-benefit assessments for neuroleptic treatment in schizophrenia is warranted.